SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 994 participants.

Also called NCT05345327

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 994 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05345327
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Sri Lanka (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05345327. Randomized; quadruple masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Acronym
START
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Metformin
Lead sponsor
The George Institute (class: other)
Collaborator
The University of New South Wales (class: other)
Collaborator
Monash University (class: other)
Collaborator
University of Sydney (class: other)

Record details

Record id
cardio:ct-nct05345327
Content hash
393a37ad8f950602cc2196756ad72b1bed2a3240da2a2c6be7ef66618fc7135f